Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Will genomics revolutionise pharmaceutical R&D?

Denis Noble1

  • 1University Laboratory of Physiology, Parks Road, Oxford OX1 3PT, UK. denis.noble@physiol.ox.ac.uk

Trends in Biotechnology
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How physiology solves the gene-centric impasse.

Experimental physiology·2026
Same author

The principles of systems biology.

Experimental physiology·2026
Same author

There are more things in heaven and Earth than we dream of in our physiology.

The Journal of physiology·2025
Same author

The cardiac pacemakers: A paradigm of robustness in evolutionary biology.

The Journal of physiology·2025
Same author

Extracellular Vesicles as Targeted Communicators in Complementary Medical Treatments.

International journal of molecular sciences·2025
Same author

New lessons from biology for economics and business: a systems approach to non-market environments.

Journal of the Royal Society, Interface·2024
Same journal

A caspase-3-activated protein expression system for apoptosis visualization and apoptosis-pyroptosis conversion to boost antitumor activity.

Trends in biotechnology·2026
Same journal

Over 4 months of ethylene production using solid-state photosynthetic cell factories.

Trends in biotechnology·2026
Same journal

Closing the nitrogen loop in groundwater with biohybrid technologies.

Trends in biotechnology·2026
Same journal

Engineering environmental bacteria for whole-cell PET hydrolysis and assimilation.

Trends in biotechnology·2026
Same journal

Acoustic cavitation-enhanced lymphatic trafficking of inhaled bacterial-sourced biohybrid vaccines for antitumor immunity.

Trends in biotechnology·2026
Same journal

Make uphill thermodynamics downhill in pathway design.

Trends in biotechnology·2026
See all related articles

Understanding cellular and systemic interactions is key for identifying drug targets. Integrating systems biology with genomics and proteomics, via in silico simulation, will revolutionize drug discovery, but requires higher-level experimental data.

Area of Science:

  • Systems biology and computational drug discovery.

Background:

  • Drug target identification necessitates understanding complex interactions within biological systems, not just genomic or proteomic data.
  • Disease states involve altered functional interactions at cellular, organ, and systemic levels, information not present in genomics alone.

Purpose of the Study:

  • To highlight the necessity of understanding high-level functional interactions for successful drug target identification.
  • To emphasize the transformative potential of in silico simulation, integrating multi-omics data for drug discovery.

Main Methods:

  • Leveraging advancements in biological databases, computational modeling, and processing power.
  • Integrating genomic and proteomic data with in silico simulation technologies.

Main Results:

Related Experiment Videos

  • In silico simulation, combined with multi-omics data, can explore functionality from genes to whole systems.
  • This approach has the potential to revolutionize all stages of pharmaceutical research and development.

Conclusions:

  • Understanding the logic of healthy and diseased states through systems-level interactions is crucial for genomics to revolutionize drug discovery.
  • The primary challenge remains acquiring experimental data at levels beyond genomics and proteomics to fully realize the potential of in silico approaches.